Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Diabetic Retinopathy Progression in Anti-VEGF versus Fluocinolone Acetonide Implant Treated Eyes Who are Lost to Follow-up
Caesar K. Luo, MD, FASRS
Updates from the Field
2020
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2022
Suprachoroidal Triamcinolone Acetonide with and without Intravitreal Aflibercept for Diabetic Macular Edema: Results of the 6-Month Prospective, Phase 1/2 Hulk Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2017

Category: Diabetic Retinopathy

See more